Company Description
At Acesis, we are on a mission to transform the way low-T or deficiency is treated. Our unique solution is rooted in the science, developed by Dr. Vassilios Papadopoulos D.Pharm., Ph.D., D.S.C., a leading expert in the steroid biochemistry field, Professor of Pharmacology and Pharmaceutical Sciences and Medicine at the University of Southern California. His research has led to a better understanding of the pathways leading to steroid hormone synthesis, the pharmacology of steroid formation in the periphery and brain, and the identification of new molecules targeting key elements in diseases where steroids play a determining role. He has discovered a novel mechanism of action and developed a drug pipeline of short peptides targeting testosterone biosynthesis which can induce the cells of the testis to produce the natural hormone. His work has been published extensively in peer-reviewed publications and cited over 32,000 times. The drug pipeline of peptides is protected by two patent families owned by Acesis. The patent covering our lead compounds is valid until the year 2040 in the US.It is our goal to provide a novel treatment to men to restore low testosterone; unlike traditional testosterone replacement therapies, where synthetic hormones are introduced to the body via gels, injections, pellets, pills, nasal sprays, etc., with known side effects, our solution is focused on signaling the body to produce its own natural testosterone.